Sometimes, when something is broken, the first step to fixing it is to break it even more. Scientists have discovered this is the case for a human DNA repair protein that functions by marking and then further breaking damaged DNA. Their surprising findings have provided much-needed insight into how DNA repair works in healthy cells, as well as how different mutations can translate into different diseases and cancer.
Distinguished senior scientist Mina Bissell is one of five recipients of the 2020 Canada Gairdner International Award – an annual honor given to scientists who have contributed to transformative human health research.
An investigational cancer drug that targets tumors caused by mutations in the KRAS gene will be evaluated in phase 2 clinical trials, following promising safety and efficacy results in preliminary human studies and excellent results in animal studies. The drug, developed by Amgen and currently referred to as AMG 510, is the first therapy to reach clinical
Mice have been instrumental in the study of cancer, but like all animal models of human diseases, they have their limitations. For stomach cancer in particular, mice have historically been regarded as quite poor research organisms because rodents rarely develop spontaneous stomach tumors. But results from a new study are about to shake up the paradigm.
Mina Bissell, a distinguished scientist at the Berkeley Lab, has been selected to receive two prestigious awards for her pioneering contributions to breast cancer biology and medicine.
A research team has demonstrated how light-emitting nanoparticles, developed at Berkeley Lab, can be used to see deep in living tissue. Researchers hope they can be made to attach to specific components of cells to serve in an advanced imaging system that can pinpoint even single cancer cells.
A protein called XPG plays a previously unknown and critical role helping to maintain genome stability in human cells. It may also help prevent breast, ovarian, and other cancers associated with defective BRCA genes.
Berkeley Lab researchers have developed the first clinically-relevant mouse model of human breast cancer to successfully express functional estrogen receptor positive adenocarcinomas.
This model should be a powerful tool for testing therapies for aggressive ER+ breast cancers and for studying luminal cancers — the most prevalent and deadliest forms of breast cancer.
Berkeley Lab researchers have developed a new family of nanocarriers, called “3HM,” that meets all the size and stability requirements for effectively delivering therapeutic drugs to the brain for the treatment of a deadly form of cancer known as glioblastoma multiforme.
Berkeley Lab researchers have been awarded $1.3 million for two sets of studies to better understand the health impacts of thirdhand smoke, the noxious residue that clings to virtually all indoor surfaces long after the secondhand smoke from a cigarette has cleared out.